Mitochondrial dysfunction is a hallmark of early diabetes. Previous studies suggest that Argonaute-2 (AGO-2) supplementation enhances mitochondrial gene expression and improves cellular stability. Here, we investigated AGO-2 expression during diabetic myocardial injury and designed a multifunctional nanocarrier to selectively deliver AGO-2 to cardiac mitochondria, aiming to restore mitochondrial homeostasis and mitigate oxidative stress. We employed an extremely small iron oxide (ESIO) nanoparticle core functionalized with cardiac-homing peptide (CHP) and the mitochondrial-targeting peptide SS-31 to construct a targeted platform, denoted ESIO-SS-31-CHP (ESC). AGO-2 was stably incorporated via phenylboronic acid by B-N binding, yielding ESC-AGO-2. Structural and functional characterizations demonstrated efficient targeting and carrier stability. In diabetic mice, AGO-2 localization in mitochondria was downregulated at 4 weeks and exhibited impaired mitochondrial translocation. ESC-AGO-2 effectively localized to mitochondria in vitro and in vivo, leading to improved mitochondrial performance, reduced oxidative damage, and attenuated inflammatory responses. These findings highlight AGO-2 as a potential biomarker for early diabetes and introduce ESC-AGO-2 as a promising nanomedicine strategy for precision intervention at the onset of diabetic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Du et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: